Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 1, 2008, Pages 61-63

  Quereda, Carmen ^a   Corral, Iñigo ^a   Moreno, Ana ^a   Pérez Elías, María J ^a   Casado, José L ^a   Dronda, Fernando ^a   Rodríguez Sagrado, Miguel A ^a   Hernández, Beatríz ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Efavirenz; HCV; HIV; IFN; Neuropsychiatric side effects

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; EFAVIRENZ; HYPNOTIC AGENT; METHADONE; PEGINTERFERON ALPHA; RIBAVIRIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ANTIVIRAL THERAPY; ANXIETY; APATHY; ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; MIXED INFECTION; MOOD DISORDER; NEUROLOGICAL COMPLICATION; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; ANXIETY DISORDER; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG COMBINATION;

ANTI-HIV AGENTS; ANXIETY DISORDERS; BENZOXAZINES; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MENTAL DISORDERS; MOOD DISORDERS;

EID: 52049122205     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbeb9     Document Type: Article

References (10)

1. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
2. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc. 2004;292:2839-2848.
3. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67-73.
4. Malek-Ahmadi O, Hilsabeck RC. Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry. 2007;19:113-123.
5. Staszewski S, Morales-Ramirez J, Tashima KT. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. N Engl J Med. 1999;341:1865-1873.
6. Fumaz CR, Muñoz-Moreno JA, Moltó J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560-565.
7. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005;41(Suppl 1):S89-S95.
8. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005;40:588-593.
9. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther. 2004;9:905-909.
10. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.